158 related articles for article (PubMed ID: 31908768)
1. Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension.
Bouzina H; Hesselstrand R; Rådegran G
Pulm Circ; 2019; 9(4):2045894019895446. PubMed ID: 31908768
[TBL] [Abstract][Full Text] [Related]
2. Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension.
Bouzina H; Hesselstrand R; Rådegran G
Scand Cardiovasc J; 2021 Feb; 55(1):35-42. PubMed ID: 32597241
[TBL] [Abstract][Full Text] [Related]
3. Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.
Bouzina H; Rådegran G
Pulm Circ; 2020; 10(3):2045894020931317. PubMed ID: 32595932
[TBL] [Abstract][Full Text] [Related]
4. Low plasma stem cell factor combined with high transforming growth factor-α identifies high-risk patients in pulmonary arterial hypertension.
Bouzina H; Rådegran G
ERJ Open Res; 2018 Oct; 4(4):. PubMed ID: 30443557
[TBL] [Abstract][Full Text] [Related]
5. Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension.
Arvidsson M; Ahmed A; Säleby J; Hesselstrand R; Rådegran G
Pulm Circ; 2022 Jan; 12(1):e12041. PubMed ID: 35506077
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma levels of adrenomedullin in patients with pulmonary hypertension.
Kakishita M; Nishikimi T; Okano Y; Satoh T; Kyotani S; Nagaya N; Fukushima K; Nakanishi N; Takishita S; Miyata A; Kangawa K; Matsuo H; Kunieda T
Clin Sci (Lond); 1999 Jan; 96(1):33-9. PubMed ID: 9857104
[TBL] [Abstract][Full Text] [Related]
7. A study of clinical and physiological relations of daily physical activity in precapillary pulmonary hypertension.
Panagiotou M; Johnson MK; Louvaris Z; Baker JS; Church AC; Peacock AJ; Vogiatzis I
J Appl Physiol (1985); 2017 Oct; 123(4):851-859. PubMed ID: 28663381
[TBL] [Abstract][Full Text] [Related]
8. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension.
Kielstein JT; Bode-Böger SM; Hesse G; Martens-Lobenhoffer J; Takacs A; Fliser D; Hoeper MM
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1414-8. PubMed ID: 15860741
[TBL] [Abstract][Full Text] [Related]
9. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
[TBL] [Abstract][Full Text] [Related]
10. Quality of Life is Related to Haemodynamics in Precapillary Pulmonary Hypertension.
Arvanitaki A; Mouratoglou SA; Evangeliou A; Grosomanidis V; Hadjimiltiades S; Skoura L; Feloukidis C; Farmakis D; Karvounis H; Giannakoulas G
Heart Lung Circ; 2020 Jan; 29(1):142-148. PubMed ID: 30686644
[TBL] [Abstract][Full Text] [Related]
11. Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension.
Ahmed A; Ahmed S; Rådegran G
Pulm Circ; 2021; 11(4):20458940211041500. PubMed ID: 34616545
[TBL] [Abstract][Full Text] [Related]
12. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
[TBL] [Abstract][Full Text] [Related]
13. Treatment goals of pulmonary hypertension.
McLaughlin VV; Gaine SP; Howard LS; Leuchte HH; Mathier MA; Mehta S; Palazzini M; Park MH; Tapson VF; Sitbon O
J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D73-81. PubMed ID: 24355644
[TBL] [Abstract][Full Text] [Related]
14. [The value of brain natriuretic peptide in connective tissue diseases associated with pulmonary arterial hypertension].
Tian Z; Guo XX; Li MT; Wang Q; Liu YT; Zhao JL; Fang Q; Zeng XF
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):102-6. PubMed ID: 21418827
[TBL] [Abstract][Full Text] [Related]
15. Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension.
Chen G; Yang T; Gu Q; Ni XH; Zhao ZH; Ye J; Meng XM; Liu ZH; He JG; Xiong CM
Respirology; 2014 May; 19(4):608-15. PubMed ID: 24689969
[TBL] [Abstract][Full Text] [Related]
16. Plasma Growth Differentiation Factor-15 is a Potential Biomarker for Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.
Li G; Li Y; Tan XQ; Jia P; Zhao J; Liu D; Wang T; Liu B
Pediatr Cardiol; 2017 Dec; 38(8):1620-1626. PubMed ID: 28819713
[TBL] [Abstract][Full Text] [Related]
17. Assessment of right ventricular longitudinal strain by 2D speckle tracking imaging compared with RV function and hemodynamics in pulmonary hypertension.
Li Y; Wang Y; Meng X; Zhu W; Lu X
Int J Cardiovasc Imaging; 2017 Nov; 33(11):1737-1748. PubMed ID: 28553693
[TBL] [Abstract][Full Text] [Related]
18. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension.
Ogihara Y; Yamada N; Dohi K; Matsuda A; Tsuji A; Ota S; Ishikura K; Nakamura M; Ito M
J Cardiol; 2014 Feb; 63(2):149-53. PubMed ID: 24012334
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma sRAGE and IGFBP7 in heart failure decrease after heart transplantation in association with haemodynamics.
Ahmed A; Ahmed S; Arvidsson M; Bouzina H; Lundgren J; Rådegran G
ESC Heart Fail; 2020 Oct; 7(5):2340-2353. PubMed ID: 32548968
[TBL] [Abstract][Full Text] [Related]
20. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
Reesink HJ; van der Plas MN; Verhey NE; van Steenwijk RP; Kloek JJ; Bresser P
J Thorac Cardiovasc Surg; 2007 Feb; 133(2):510-6. PubMed ID: 17258590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
